Needs Assessment: The majority of psychiatrists are aware of the role played by dopamine in schizophrenia. In contrast, the role played by the neurotransmitter glutamate is relatively underappreciated. Disturbances in neurotransmission mediated at N-methyl-D-aspartate-type glutamate receptors may be of particular importance to schizophrenia. Agents that modulate glutamatergic neurotransmission are currently undergoing clinical investigation. Clinicians must understand the physiology of glutamate in order to understand the basis for new treatment development in schizophrenia and other neuropsychiatric disorders.
• Describe the role of the neurotransmitter glutamate in normal brain function.
• Enumerate the different types of glutamate receptors.
• Describe the role played by glutamatergic systems in the etiology of schizophrenia and other neuropsychiatric disorders.
• Assess the potential clinical utility of specific glutamatergic treatments.
Target Audience: Primary care physicians and psychiatrists.
CME Accreditation Statement: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: The Mount Sinai School of Medicine designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosure Policy Statement: It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
This activity has been peer-reviewed and approved by Eric Hollander, MD, chair at Mount Sinai School of Medicine. Review Date: September 20, 2006.
To receive credit for this activity: Read this article and the two CME-designated accompanying articles, reflect on the information presented, and then complete the CME quiz. To obtain credits, you should score 70% or better. Termination date: October 31, 2008. The estimated time to complete all three articles and the quiz is 3 hours.
Primary Psychiatry. 2006;13(10):38-46